PROGRAM LEARNING OBJECTIVES
At the conclusion of this live activity, participants will be able to:
1. Identify principles of clinical trial design as they apply to studies of imaging technologies for diagnosis and disease monitoring, screening, and image-guided therapy.
2. Implement the principles for incorporating imaging as a primary or important secondary endpoint in therapeutic trials.
3. Comprehend the regulatory, funding and other implementation issues associated with clinical trials using imaging.
4. Develop a clinical trial protocol for the evaluation of an imaging modality or for the use of imaging as an endpoint in a therapeutic trial.

Accreditation and Designation Statement
The Radiological Society of North America (RSNA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The RSNA designates this live activity for a maximum of 42.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Disclosures – RDC 2016, RDC 2017, Planning and Faculty
The Accreditation Council for Continuing Medical Education requires that the RSNA, as an accredited provider of continuing medical education, obtain signed disclosure statements from faculty, including committee members, program planners, presenters and authors for every CME activity. The intent of this policy is not to prevent an individual with a financial disclosure from participating; however, in accordance with ACCME standards, the RSNA has developed policies and procedures to manage identified conflicts. The ACCME further requires that the RSNA provide disclosure information to all attendees prior to the education activity.

All faculty, program planners and presenters have no relevant relationships to disclose.

Todd A. Alonzo, PhD        Jeffrey G. Jarvik, MD, MPH          Mitchell D. Schnall, MD, PhD
Andriy I. Bandos, PhD        Curtis P. Langlotz, MD, PhD       Anthony Shields, MD, PhD
Jennifer R. Bellon, MD      Janie M. Lee, MD                  Barry A. Siegel, MD
Jeffrey D. Blume, PhD        Susanna I. Lee, MD, PhD          Marilyn J. Siegel, MD
Patrick M. Bossuyt, PhD      David J. Lomas, MD                Michael C. Soulen, MD
Linda Bresolin, PhD, MBA    Mitchell Machtay, MD               Daniel C. Sullivan, MD
Ruth C. Carlos, MD, MS       Umar Mahmood, MD, PhD           Stephan D. Voss, MD, PhD
Judith Carrithers, JD       David A. Mankoff, MD, PhD         Richard L. Wahl, MD
Caroline Chung, MD, FRCPC   Diana Miglioretti, PhD           Jihong Wang, PhD
Maximilian Diehn, MD, PhD    Chaya Moskowitz, PhD            Jeffrey C. Weinreb, MD
Garry E. Gold, MD, MSEE     Rebecca Rakow-Penner, MD, PhD
Alexander R. Guimaraes, MD, PhD
Bruce G. Haffty, MD          Martin G. Pomper, MD, PhD
Udo Hoffmann, MD             Pina C. Sanelli, MD
Off-label Disclosure

The RSNA recognizes that at scientific meetings, faculty may discuss the application of some devices, materials, or pharmaceuticals that are not FDA approved. In keeping with the highest standards of professional integrity and ethics, it is required that faculty fully disclose to their audience that there will be discussion of the unlabeled use of a commercial product, device, or pharmaceutical that has not been approved for such purposes by the FDA.